Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27714466 | 0.89 | ALDH1A1 (0.54) | GAAALDH1A1HTTEGFRHIF1A | |
| SCHEMBL8651569 | 0.77 | ALDH1A1 (0.43) | ALDH1A1MAPTPRSS1 | |
| SCHEMBL5551251 | 0.77 | MAPT (0.59) | GAAALDH1A1HTTTHRBMAPT | |
| SCHEMBL7100388 | 0.77 | GAA (0.47) | GAAALDH1A1HTTTHRBMAPT | |
| SCHEMBL5493605 | 0.77 | LMNA (0.43) | GAAALDH1A1MAPTALDH1A3CA2 | |
| SCHEMBL5506124 | 0.76 | ALDH1A1 (0.64) | GAAALDH1A1HTTTHRBMAPT | |
| SCHEMBL5504318 | 0.76 | GAA (0.46) | GAAALDH1A1HTTTHRBMAPT | |
| SCHEMBL5543098 | 0.75 | ABL1 (0.45) | GAAALDH1A1ALDH1A3PRSS1CYP2A6 | |
| SCHEMBL12451481 | 0.75 | PRSS1 (0.42) | ALDH1A1MAPTCA2CA9APP | |
| SCHEMBL10063731 | 0.74 | ALDH1A1 (0.49) | GAAALDH1A1MAPTPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12235217-B2 | Diagnostic test kits for sample preparation and analysis | SCANWELL HEALTH, INC. (US) | 2025-02-25 | — | — | US | claimed |
| US-20250258104-A1 | DIAGNOSTIC TEST KITS FOR SAMPLE PREPARATION AND ANALYSIS | SCANWELL HEALTH INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-12235217-B2 | Diagnostic test kits for sample preparation and analysis | SCANWELL HEALTH, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-9556187-B2 | Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-3112370-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-9216999-B2 | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| US-9164376-B2 | Patterning nano-scale patterns on a film comprising unzipping copolymers | GLOBALFOUNDRIES INC. (KY) | 2015-10-20 | — | — | US | disclosed |
| EP-2742049-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-8574815-B2 | Patterning nano-scale patterns on a film comprising unzipping copolymers | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2013-11-05 | — | — | US | disclosed |
| WO-2013024895-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-02-21 | — | — | WO | disclosed |
| US-20120301672-A1 | PATTERNING NANO-SCALE PATTERNS ON A FILM COMPRISING UNZIPPING COPOLYMERS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120297905-A1 | PATTERNING NANO-SCALE PATTERNS ON A FILM COMPRISING UNZIPPING COPOLYMERS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120082944-A1 | Patterning nano-scale patterns on a film comprising unzipping copolymers | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-04-05 | — | — | US | disclosed |
| US-4540790-A | COLORFORMERS INC PRESSURE SENSITIVE CARBONLESS DUPLICATION | THE HILTON-DAVIS CHEMICAL CO. (US) | 1985-09-10 | — | — | US | disclosed |
| EP-0061128-B1 | PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND SYSTEMS CONTAINING THEM | STERLING DRUG INC. (US) | 1985-09-04 | — | — | EP | disclosed |
| US-4446321-A | COLOR FORMERS, CARBON-FREE DUPLICATION | STERLING DRUG INC. (US) | 1984-05-01 | — | — | US | disclosed |
| US-4396767-A | COLORS, CARBONLESS DUPLICATION | STERLING DRUG INC. (US) | 1983-08-02 | — | — | US | disclosed |
| US-4363503-A | FOR PRESSURE SENSITIVE CARBONLESS DUPLICATING AND THERMAL MARKING SYSTEMS | STERLING DRUG INC. (US) | 1982-12-14 | — | — | US | disclosed |
| EP-0061128-A1 | Pyridine compounds, process for their preparation and systems containing them | STERLING DRUG INC. (US) | 1982-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | JAK2, JAK1, JAK3 | GAA 3189/4885ALDH1A1 3086/4885HTT 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.